OUR PRODUCTS
Our Pipeline
We challenge ourselves to rethink the way medicines are developed,
and
are investing now to bring more value to patients in the future.
We strive for constant innovation and we are putting our passion and expertise to work in new areas including ophthalmology, gastroenterology, and hematology.
SB11i
Biosimilar candidate
- Molecule Ranibizumab
- Reference Biologic Lucentis®ii
- Therapeutic Area Ophthalmology
SB12
Biosimilar candidate
- Molecule Eculizumab
- Reference Biologic Soliris®iii
- Therapeutic Area Hematology
SB15i
Biosimilar candidate
- Molecule Aflibercept
- Reference Biologic Eylea®iv
- Therapeutic Area Ophthalmology
SB26
Novel biologic
- Molecule Ulinastatin-Fc
Fusion Protein - Therapeutic Area Gastroenterology
*Pipeline last updated Oct 2020
- iPhase I clinical trial was waived for SB11 and SB15
- iiLucentis® is a registered trademark of Genentech
- iiiSoliris® is a registered trademark of Alexion
- ivEylea® is a registered trademark of Regeneron
You are now leaving the Samsung Bioepis website.
Samsung Bioepis provides this link as a courtesy and does not control the content of the site you are about to enter into. Do you wish to continue?
